Antithrombotic Therapy for VTE Disease

Stevens, Scott M.; Woller, Scott C.; Kreuziger, Lisa Baumann; Bounameaux, Henri; Doerschug, Kevin C.; Geersing, Geert‐Jan; Huisman, Menno V.; Kearon, Clive; King, Christopher S.; Knighton, Andrew J.; Lake, Erica; Murin, Susan; Vintch, Janine; Wells, Philip S.; Moores, Lisa K.

doi:10.1016/j.chest.2021.07.055

Cited by 582 publications

(523 citation statements)

References 233 publications

(296 reference statements)

Supporting

Mentioning

379

Contrasting

Unclassified

Order By: Relevance

“…The usual first choice of treatment escalation is systemic thrombolysis (ST). 11 ST leads to rapid resolution of embolic obstruction restoring pulmonary perfusion. Thrombolytic agents, such as tissue plasminogen activator (tPA), alteplase, promise thrombus resolution within few hours.…”

Section: Primary Treatment Options For Massive Pulmonary Embolismmentioning

confidence: 99%

Management of Massive Pulmonary Embolism

Poláková

Veselka

2022

Int J Angiol

View full text Add to dashboard Cite

Pulmonary embolism is a potentially lethal manifestation of venous thromboembolic disease. It is one of the three main causes of cardiovascular morbidity and mortality in developed countries. Over the years, better diagnostic and risk stratification measures were implemented. A generous range of new treatment options is becoming available, particularly for management of massive pulmonary embolism. Nonetheless, clinicians often face uncertainty in clinical practice due to lack of scientific support for available treatment options. The aim of this article is to review management of massive pulmonary embolism.

show abstract

Section: Primary Treatment Options For Massive Pulmonary Embolismmentioning

confidence: 99%

Management of Massive Pulmonary Embolism

Poláková

Veselka

2022

Int J Angiol

View full text Add to dashboard Cite

show abstract

“…Hingegen gelten DOAK für Schwangere, APS-Patienten mit Tripelpositivität und/oder arteriellen Thrombosen sowie Patienten mit schwerer Niereninsuffizienz als kontraindiziert 35 36 .…”

Section: Implikationen Für Wahl Der Therapiestrategieunclassified

“…Für die iliofemorale Venenthrombose – mit und ohne VCI-Beteiligung – konnten randomisierte kontrollierte Studien zwar eine geringere Rate bzw. Ausprägung eines PTS nachweisen; im Hinblick auf die klinisch entscheidenden Endpunkte Lungenembolie, Rezidiv-VTE und Tod ergaben sich hingegen für die endovaskuläre Therapie keine Vorteile im Vergleich zur alleinigen Antikoagulation 36 .…”

Section: Implikationen Für Wahl Der Therapiestrategieunclassified

Thrombosen der Vena cava inferior – Ursachen und therapeutische Implikationen

Linnemann¹,

Putz²,

Pfister³

2022

Gefäßmedizin Scan - Zeitschrift für Angiologie, Gefäßchirurgie,

View full text Add to dashboard Cite

“…79 108 The 2009 ACCP guidelines include inherited thrombophilia (with a 1.5 relative risk of recurrence) among “additional factors to predict risk of recurrence, but not strongly or consistently enough to influence recommendations on duration of therapy.” 108 The 2021 ACCP guidelines recommend short-term anticoagulation (i.e., 3 months) for VTE provoked by major and minor transient risk factors, while recommending extended anticoagulation for unprovoked or provoked by persistent risk factor VTE. 109 As extended anticoagulation therapy, the panel suggests the use of reduced-dose over full-dose DOACs. 109 Intrinsic patient characteristics that affect susceptibility to VTE, such as sex, the presence of hereditary thrombophilia, ABO blood type, or age were not classified as persistent risk factors, thus thrombophilia does not necessarily imply the need for extended anticoagulation therapy.…”

Section: Acute Management Of Vte and Secondary Prevention In Heredita...mentioning

confidence: 99%

“…109 As extended anticoagulation therapy, the panel suggests the use of reduced-dose over full-dose DOACs. 109 Intrinsic patient characteristics that affect susceptibility to VTE, such as sex, the presence of hereditary thrombophilia, ABO blood type, or age were not classified as persistent risk factors, thus thrombophilia does not necessarily imply the need for extended anticoagulation therapy. 109 The 2020 ASH Guidelines include hereditary thrombophilia among non-environmental risk factors, along with older age and male sex.…”

Section: Acute Management Of Vte and Secondary Prevention In Heredita...mentioning

confidence: 99%

Evolving Knowledge on Primary and Secondary Prevention of Venous Thromboembolism in Carriers of Hereditary Thrombophilia: A Narrative Review

Campello

Prandoni²

2022

Semin Thromb Hemost

View full text Add to dashboard Cite

The association between heritability of venous thromboembolism (VTE) and thrombophilia was first reported clinically in 1956, later followed by the first description of a congenital cause of hypercoagulability—antithrombin deficiency—in 1965. Since then, our knowledge of hereditary causes of hypercoagulability, which may predispose carriers to VTE has improved greatly. Novel genetic defects responsible for severe thrombophilia have been recently identified and we have learned that a wide range of interactions between thrombophilia and other genetic and acquired risk factors are important determinants of the overall individual risk of developing VTE. Furthermore, therapeutic strategies in thrombophilic patients have benefited significantly from the introduction of direct oral anticoagulants. The present review is an overview of the current knowledge on the mechanisms underlying inherited thrombophilia, with a particular focus on the latest achievements in anticoagulation protocols and prevention strategies for thrombosis in carriers of this prothrombotic condition.

show abstract

Antithrombotic Therapy for VTE Disease

Cited by 582 publications

References 233 publications

Management of Massive Pulmonary Embolism

Management of Massive Pulmonary Embolism

Thrombosen der Vena cava inferior – Ursachen und therapeutische Implikationen

Evolving Knowledge on Primary and Secondary Prevention of Venous Thromboembolism in Carriers of Hereditary Thrombophilia: A Narrative Review

Contact Info

Product

Resources

About